Biosciences Area

  • About Biosciences
    • Leadership
    • Area Operations Centers
    • Strategic Plan and Reports
    • Strategic Programs Development Group
    • Contact Information
  • Our Science
    • Area Programs
    • Strategic Initiatives
    • Biological Systems and Engineering
    • Environmental Genomics and Systems Biology
    • Molecular Biophysics and Integrated Bioimaging
    • DOE Joint Genome Institute
  • Media and Events
    • News
    • Announcements
    • Behind the Breakthroughs
    • Events Calendar
    • Seminar Series
  • Staff Resources
    • Commonly Used Acronyms
    • Communications
    • Hiring and Recruitment
    • Hybrid & Telework Resources
    • IDEA
    • Intellectual Property, Industry Engagement, and Entrepreneurship
    • LDRD Information
    • Logos and Templates
    • Mentoring Program
  • Search

Bay Area Biopharma Company Uses ALS to Tackle Sickle Cell Disease

September 1, 2017

The structure of a compound that GBT studied at the ALS
The structure of a compound that GBT studied at the ALS. This model of the hemoglobin S tetramer bound to the compound shows how the compound helps stabilize hemoglobin to prevent sickling.

The protein crystallography capabilities at the Advanced Light Source’s (ALS’s) Beamline 8.3.1 have been critical to Global Blood Therapeutics’ (GBT’s) ongoing effort to formulate a better treatment for sickle cell disease (SCD). The Bay Area biopharmaceutical company is developing a therapy that prevents the polymerization of hemoglobin, the key event in promoting the sickle shape and advancing the disease. Working closely with beamline scientist and Biosciences (MBIB) faculty James Holton, GBT obtained results from the ALS that enabled them to understand the molecular mechanism of their compound GBT440—which works by binding to hemoglobin and increasing the affinity for oxygen, thereby inhibiting polymerization—and gain insight into other potential molecular targets. Much of the research GBT conducts is confidential, but the company has already published two papers based on their work at the ALS. The compound GBT440 is currently in phase 3 clinical trials. Read more from ALS News.

 

Was this page useful?

Send
like not like

About Biosciences

  • Leadership
  • Area Operations Centers
  • Inclusion, Diversity, Equity, and Accountability (IDEA)
  • Contact

Divisions & User Facility

  • Biological Systems and Engineering
  • Environmental Genomics and Systems Biology
  • Molecular Biophysics and Integrated Bioimaging
  • DOE Joint Genome Institute

Resources

  • A-Z Index
  • Phonebook
  • Logos
  • Acronyms
  • Integrated Safety Management
Questions & Comments
Follow us: Mastodon LinkedIn YouTube